Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Comparative toxicities and mutagenicities of platinum anticancer drugs
K. J. Yarema
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Comparative toxicities and mutagenicities of platinum anticancer drugs'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
2-amino-3-cyano-6-methyl-5-(3,4-dimethoxyphenyl)pyridine
100%
Platinum
69%
Cisplatin
59%
cisplatin-DNA adduct
38%
Platinum Compounds
32%
Pharmaceutical Preparations
27%
DNA
24%
Genome
14%
DNA Adducts
13%
Single-Stranded DNA
13%
Antineoplastic Agents
10%
Poisons
8%
Carcinoma
7%
Clinical Trials
7%
Drug Therapy
6%
Safety
6%
Mutation
6%
Therapeutics
3%
Neoplasms
3%
Chemical Compounds
Cisplatin
57%
Platinum
48%
Adduct
47%
Drug
34%
Carcinogenic
13%
Antineoplastic Agent
5%
Safety
5%
Mutation
5%
Toxic
4%
Social Sciences
drug
44%
Clinical Trials
17%
cancer
15%
evaluation
15%
liability
14%
candidacy
12%
inclusion
11%
experiment
9%